Fulgent Genetics (FLGT) Stock Forecast, Price Target & Predictions
FLGT Stock Forecast
Fulgent Genetics stock forecast is as follows: an average price target of $45.00 (represents a 96.42% upside from FLGT’s last price of $22.91) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
FLGT Price Target
The average price target for Fulgent Genetics (FLGT) is $45.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $50.00 to $40.00. This represents a potential 96.42% upside from FLGT's last price of $22.91.
FLGT Analyst Ratings
According to 2 Wall Street analysts, Fulgent Genetics's rating consensus is 'Buy'. The analyst rating breakdown for FLGT stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Fulgent Genetics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 08, 2022 | - | Piper Sandler | $40.00 | $37.07 | 7.90% | 74.60% |
| Nov 18, 2022 | - | Raymond James | $45.00 | $35.89 | 25.38% | 96.42% |
| Nov 14, 2022 | - | Credit Suisse | $50.00 | $39.24 | 27.42% | 118.25% |
| May 15, 2022 | David Westenberg | Piper Sandler | $70.00 | $54.45 | 28.56% | 205.54% |
The latest Fulgent Genetics stock forecast, released on Dec 08, 2022 by Piper Sandler company, set a price target of $40.00, which represents a 7.90% increase from the stock price at the time of the forecast ($37.07), and a 74.60% increase from FLGT last price ($22.91).
Fulgent Genetics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $22.91 | $22.91 | $22.91 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Fulgent Genetics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Fulgent Genetics's last price of $22.91. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 08, 2022 | Piper Sandler | Overweight | Neutral | Downgrade |
| Nov 18, 2022 | Raymond James | - | Outperform | Initialise |
| Nov 14, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Fulgent Genetics's last stock rating was published by Piper Sandler on Dec 08, 2022. The company Downgrade its FLGT rating from "Overweight" to "Neutral".
Fulgent Genetics Financial Forecast
Fulgent Genetics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $84.69M | $67.85M | $66.17M | $67.70M | $105.66M | $125.34M | $320.27M | $251.67M | $227.87M | $153.62M | $359.43M | $294.98M | $101.72M | $17.27M | $7.75M | $8.39M | $10.35M |
| Avg Forecast | $95.42M | $92.26M | $90.15M | $82.94M | $85.37M | $82.72M | $80.34M | $73.48M | $74.87M | $71.72M | $69.07M | $65.36M | $66.32M | $64.42M | $62.48M | $60.05M | $59.57M | $91.36M | $122.70M | $270.85M | $191.10M | $264.00M | $197.34M | $321.51M | $199.46M | $48.46M | $10.02M | $7.74M | $8.51M | $8.44M |
| High Forecast | $96.21M | $93.04M | $90.90M | $83.63M | $86.09M | $83.42M | $81.02M | $74.09M | $75.49M | $72.43M | $69.64M | $65.91M | $66.37M | $64.96M | $63.01M | $60.55M | $60.07M | $92.12M | $123.82M | $273.33M | $192.85M | $266.42M | $199.15M | $324.46M | $201.29M | $48.91M | $10.11M | $7.81M | $8.58M | $8.52M |
| Low Forecast | $94.06M | $90.95M | $88.87M | $81.76M | $84.16M | $81.55M | $79.20M | $72.43M | $73.80M | $70.99M | $68.08M | $64.43M | $66.28M | $63.50M | $61.59M | $59.20M | $58.72M | $90.06M | $121.21M | $267.56M | $188.78M | $260.79M | $194.94M | $317.61M | $197.04M | $47.87M | $9.90M | $7.64M | $8.40M | $8.34M |
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 10 | 16 | 8 | 11 | 7 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.31% | 1.09% | 1.10% | 1.14% | 1.16% | 1.02% | 1.18% | 1.32% | 0.86% | 0.78% | 1.12% | 1.48% | 2.10% | 1.72% | 1.00% | 0.99% | 1.23% |
Fulgent Genetics's average Quarter revenue forecast for Dec 23 based on 2 analysts is $66.32M, with a low forecast of $66.28M, and a high forecast of $66.37M. FLGT's average Quarter revenue forecast represents a -21.69% decrease compared to the company's last Quarter revenue of $84.69M (Sep 23).
Fulgent Genetics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 10 | 16 | 8 | 11 | 7 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $214.00K | $-19.80M | $-22.86M | $-34.59M | $2.57M | $26.93M | $202.84M | $155.01M | $163.74M | $106.42M | $269.41M | $226.59M | $62.31M | $3.55M | $-1.11M | $473.00K | $2.03M |
| Avg Forecast | $28.92M | $27.97M | $27.33M | $25.14M | $25.88M | $25.08M | $24.35M | $22.27M | $22.69M | $21.74M | $20.94M | $19.81M | $20.10M | $19.53M | $18.94M | $18.20M | $18.06M | $27.69M | $37.19M | $141.67M | $57.93M | $80.02M | $59.82M | $239.07M | $60.46M | $14.69M | $3.04M | $-3.50M | $2.58M | $2.56M |
| High Forecast | $29.16M | $28.20M | $27.56M | $25.35M | $26.09M | $25.29M | $24.56M | $22.46M | $22.88M | $21.96M | $21.11M | $19.98M | $20.12M | $19.69M | $19.10M | $18.36M | $18.21M | $27.92M | $37.53M | $170.01M | $58.46M | $80.76M | $60.37M | $286.88M | $61.01M | $14.82M | $3.07M | $-2.80M | $2.60M | $2.58M |
| Low Forecast | $28.51M | $27.57M | $26.94M | $24.78M | $25.51M | $24.72M | $24.01M | $21.96M | $22.37M | $21.52M | $20.64M | $19.53M | $20.09M | $19.25M | $18.67M | $17.94M | $17.80M | $27.30M | $36.74M | $113.34M | $57.22M | $79.05M | $59.09M | $191.25M | $59.73M | $14.51M | $3.00M | $-4.20M | $2.55M | $2.53M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.01% | -1.05% | -1.26% | -1.92% | 0.09% | 0.72% | 1.43% | 2.68% | 2.05% | 1.78% | 1.13% | 3.75% | 4.24% | 1.17% | 0.32% | 0.18% | 0.79% |
2 analysts predict FLGT's average Quarter EBITDA for Dec 23 to be $20.10M, with a high of $20.12M and a low of $20.09M. This is 9294.14% upper than Fulgent Genetics's previous annual EBITDA (Sep 23) of $214.00K.
Fulgent Genetics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 10 | 16 | 8 | 11 | 7 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-13.11M | $-11.23M | $-15.85M | $-24.08M | $1.34M | $11.54M | $153.98M | $103.68M | $122.52M | $79.81M | $200.69M | $166.31M | $46.64M | $3.32M | $-1.96M | $-296.00K | $1.46M |
| Avg Forecast | $-8.86M | $-903.69K | $833.99K | $-2.22M | $-9.68M | $-2.74M | $-1.36M | $-4.43M | $-11.66M | $-4.47M | $-8.99M | $127.43M | $-8.61M | $-9.63M | $-9.88M | $115.84M | $-16.86M | $137.88M | $21.97M | $105.31M | $78.42M | $97.82M | $82.97M | $178.09M | $118.51M | $16.59M | $-1.27M | $-6.16M | $593.26K | $902.94K |
| High Forecast | $-8.70M | $-886.98K | $843.05K | $-2.18M | $-9.50M | $-2.69M | $-1.33M | $-4.35M | $-11.45M | $-4.39M | $-8.82M | $152.91M | $-6.60M | $-9.45M | $-9.69M | $139.01M | $-16.55M | $165.46M | $22.23M | $126.37M | $79.35M | $98.98M | $83.96M | $213.71M | $119.92M | $16.79M | $-1.25M | $-4.93M | $600.32K | $913.68K |
| Low Forecast | $-8.96M | $-913.52K | $818.57K | $-2.24M | $-9.78M | $-2.77M | $-1.37M | $-4.48M | $-11.79M | $-4.54M | $-9.09M | $101.94M | $-10.62M | $-9.74M | $-9.98M | $92.67M | $-17.04M | $110.31M | $21.62M | $84.25M | $77.18M | $96.27M | $81.66M | $142.47M | $116.64M | $16.33M | $-1.29M | $-7.39M | $583.89K | $888.67K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.36% | 1.14% | -0.14% | 1.43% | 0.01% | 0.53% | 1.46% | 1.32% | 1.25% | 0.96% | 1.13% | 1.40% | 2.81% | -2.61% | 0.32% | -0.50% | 1.62% |
Fulgent Genetics's average Quarter net income forecast for Dec 22 is $-16.86M, with a range of $-17.04M to $-16.55M. FLGT's average Quarter net income forecast represents a -1355.40% decrease compared to the company's last Quarter net income of $1.34M (Sep 22).
Fulgent Genetics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 10 | 16 | 8 | 11 | 7 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $27.66M | $28.72M | $31.89M | $39.05M | $36.13M | $41.11M | $33.72M | $30.30M | $18.31M | $13.55M | $13.01M | $12.72M | $8.76M | $5.06M | $3.63M | $3.37M | $3.21M |
| Avg Forecast | $23.27M | $22.50M | $21.98M | $20.22M | $20.82M | $20.17M | $19.59M | $17.92M | $18.26M | $17.49M | $16.84M | $27.90M | $16.17M | $15.71M | $15.24M | $25.36M | $14.53M | $20.61M | $29.92M | $23.06M | $46.60M | $64.37M | $48.12M | $11.54M | $48.64M | $11.82M | $2.44M | $1.89M | $2.07M | $2.06M |
| High Forecast | $23.46M | $22.69M | $22.17M | $20.39M | $20.99M | $20.34M | $19.76M | $18.07M | $18.41M | $17.66M | $16.98M | $33.48M | $16.18M | $15.84M | $15.36M | $30.44M | $14.65M | $24.73M | $30.19M | $27.67M | $47.02M | $64.96M | $48.56M | $13.85M | $49.08M | $11.93M | $2.47M | $1.90M | $2.09M | $2.08M |
| Low Forecast | $22.94M | $22.18M | $21.67M | $19.94M | $20.52M | $19.88M | $19.31M | $17.66M | $18.00M | $17.31M | $16.60M | $22.32M | $16.16M | $15.49M | $15.02M | $20.29M | $14.32M | $16.49M | $29.56M | $18.45M | $46.03M | $63.59M | $47.54M | $9.24M | $48.05M | $11.67M | $2.41M | $1.86M | $2.05M | $2.03M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.76% | 1.88% | 1.26% | 2.69% | 1.75% | 1.37% | 1.46% | 0.65% | 0.28% | 0.28% | 1.13% | 0.26% | 0.74% | 2.07% | 1.92% | 1.62% | 1.56% |
Fulgent Genetics's average Quarter SG&A projection for Dec 23 is $16.17M, based on 2 Wall Street analysts, with a range of $16.16M to $16.18M. The forecast indicates a -41.53% fall compared to FLGT last annual SG&A of $27.66M (Sep 23).
Fulgent Genetics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | - | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 10 | 16 | 8 | 11 | 7 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.44 | $-0.38 | $-0.54 | $-0.81 | $0.04 | $0.38 | $5.09 | $3.46 | $4.13 | $2.74 | $6.96 | $6.55 | $2.11 | $0.15 | $-0.09 | $-0.01 | $0.08 |
| Avg Forecast | $-0.29 | $-0.03 | $0.03 | $-0.07 | $-0.32 | $-0.09 | $-0.05 | $-0.15 | $-0.39 | $-0.15 | $-0.30 | $-0.32 | $-0.29 | $-0.32 | $-0.33 | $-0.43 | $-0.56 | $0.05 | $0.73 | $3.86 | $2.61 | $3.25 | $2.76 | $5.86 | $3.94 | $0.55 | $-0.04 | $0.02 | $0.02 | $0.03 |
| High Forecast | $-0.29 | $-0.03 | $0.03 | $-0.07 | $-0.32 | $-0.09 | $-0.04 | $-0.14 | $-0.38 | $-0.15 | $-0.29 | $-0.31 | $-0.22 | $-0.31 | $-0.32 | $-0.42 | $-0.55 | $0.05 | $0.74 | $3.91 | $2.64 | $3.29 | $2.79 | $5.93 | $3.98 | $0.56 | $-0.04 | $0.02 | $0.02 | $0.03 |
| Low Forecast | $-0.30 | $-0.03 | $0.03 | $-0.07 | $-0.33 | $-0.09 | $-0.05 | $-0.15 | $-0.39 | $-0.15 | $-0.30 | $-0.32 | $-0.35 | $-0.32 | $-0.33 | $-0.43 | $-0.57 | $0.05 | $0.72 | $3.80 | $2.56 | $3.20 | $2.71 | $5.76 | $3.88 | $0.54 | $-0.04 | $0.02 | $0.02 | $0.03 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.38% | 1.16% | 1.27% | 1.45% | 0.84% | 0.52% | 1.32% | 1.33% | 1.27% | 0.99% | 1.19% | 1.66% | 3.83% | -3.54% | -4.27% | -0.51% | 2.67% |
According to 0 Wall Street analysts, Fulgent Genetics's projected average Quarter EPS for Dec 22 is $-0.56, with a low estimate of $-0.57 and a high estimate of $-0.55. This represents a -1358.81% decrease compared to FLGT previous annual EPS of $0.04 (Sep 22).
Fulgent Genetics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TTOO | T2 Biosystems | $2.15 | $5.00 | 132.56% | Hold |
| GH | Guardant Health | $25.08 | $57.27 | 128.35% | Buy |
| FLGT | Fulgent Genetics | $22.91 | $45.00 | 96.42% | Buy |
| CRL | Charles River Laboratories | $206.10 | $316.29 | 53.46% | Buy |
| ILMN | Illumina | $130.97 | $200.82 | 53.33% | Buy |
| EXAS | Exact Sciences | $69.21 | $94.33 | 36.30% | Buy |
| DHR | Danaher | $271.90 | $313.59 | 15.33% | Buy |
| TMO | Thermo Fisher Scientific | $610.12 | $647.37 | 6.11% | Buy |
| CDNA | CareDx | $29.26 | $31.00 | 5.95% | Buy |
| A | Agilent | $139.01 | $144.90 | 4.24% | Buy |
| WAT | Waters | $333.37 | $325.00 | -2.51% | Buy |
| MTD | Mettler-Toledo | $1.40K | $1.36K | -2.73% | Hold |
| TWST | Twist Bioscience | $47.02 | $42.40 | -9.83% | Buy |
| NTRA | Natera | $127.10 | $114.38 | -10.01% | Buy |
FLGT Forecast FAQ
Is Fulgent Genetics a good buy?
Yes, according to 2 Wall Street analysts, Fulgent Genetics (FLGT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of FLGT's total ratings.
What is FLGT's price target?
Fulgent Genetics (FLGT) average price target is $45 with a range of $40 to $50, implying a 96.42% from its last price of $22.91. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Fulgent Genetics stock go up soon?
According to Wall Street analysts' prediction for FLGT stock, the company can go up by 96.42% (from the last price of $22.91 to the average price target of $45), up by 118.25% based on the highest stock price target, and up by 74.60% based on the lowest stock price target.
Can Fulgent Genetics stock reach $30?
FLGT's average twelve months analyst stock price target of $45 supports the claim that Fulgent Genetics can reach $30 in the near future.
What are Fulgent Genetics's analysts' financial forecasts?
Fulgent Genetics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $321.92M (high $324.61M, low $317.34M), average EBITDA is $97.58M (high $98.4M, low $96.19M), average net income is $-18.205M (high $-17.869M, low $-18.403M), average SG&A $78.5M (high $79.15M, low $77.38M), and average EPS is $-0.605 (high $-0.594, low $-0.611). FLGT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $360.76M (high $363.78M, low $355.63M), average EBITDA is $109.36M (high $110.27M, low $107.8M), average net income is $-11.152M (high $-10.922M, low $-11.298M), average SG&A $87.97M (high $88.71M, low $86.72M), and average EPS is $-0.371 (high $-0.363, low $-0.375).
Did the FLGT's actual financial results beat the analysts' financial forecasts?
Based on Fulgent Genetics's last annual report (Dec 2023), the company's revenue was $289.21M, beating the average analysts forecast of $253.28M by 14.19%. Apple's EBITDA was $-196M, missing the average prediction of $76.77M by -354.68%. The company's net income was $-168M, missing the average estimation of $87.72M by -291.31%. Apple's SG&A was $130.47M, beating the average forecast of $72.48M by 80.00%. Lastly, the company's EPS was $-5.63, beating the average prediction of $-1.361 by 313.74%. In terms of the last quarterly report (Sep 2023), Fulgent Genetics's revenue was $84.69M, beating the average analysts' forecast of $64.42M by 31.46%. The company's EBITDA was $214K, missing the average prediction of $19.53M by -98.90%. Fulgent Genetics's net income was $-13.107M, beating the average estimation of $-9.631M by 36.09%. The company's SG&A was $27.66M, beating the average forecast of $15.71M by 76.08%. Lastly, the company's EPS was $-0.44, beating the average prediction of $-0.32 by 37.50%